{
  "filename": "83---An-18-Year-Old-Man-from-India-With-a-Pale-P_2022_Clinical-Cases-in-Trop.pdf",
  "markdown_path": "./Processed/markdown/83---An-18-Year-Old-Man-from-India-With-a-Pale-P_2022_Clinical-Cases-in-Trop.md",
  "images": [
    {
      "page": 1,
      "path": "./Processed/images/83---An-18-Year-Old-Man-from-India-With-a-Pale-P_2022_Clinical-Cases-in-Trop/83---An-18-Year-Old-Man-from-India-With-a-Pale-P_2022_Clinical-Cases-in-Trop_p1_img1.jpeg"
    }
  ],
  "table_text": "TABLE 83.1 WHO Classification of Leprosy and Recommended Duration of Treatment\n| Classification | Number of Patches | Duration of Treatment |\n|---|---|---|\n| Paucibacillary | 5 | 6 months |\n\nTABLE 83.2 WHO Treatment of Leprosy (2018)\n| Drug | Once Monthly Dose | All Other Days Daily Dose |\n|---|---|---|\n| Rifampicin | 600 mg | - |\n| Clofazimine | 300 mg | 50 mg |\n| Dapsone | 100 mg | 100 mg |",
  "table_source": "/Users/macintoshhd/Downloads/Project-Dr.Khanh/Clinical-RAG/Processed/out_all_structured/83---An-18-Year-Old-Man-from-India-With-a-Pale-P_2022_Clinical-Cases-in-Trop-tables.md",
  "table_label": "TABLE 83.1",
  "table_caption": "WHO Classification of Leprosy and Recommended Duration of Treatment"
}